The Evolution and Future of Targeted Protein Degradation Chemistry Shorts

1. FDA Approval Proof Point Not Enough To Inform Other TPD Targets 7/23/2026

   Maria Soloveychik says the approval of a bivalent degrader is an important proof point for the field, showing that these compounds can work clinically much like molecular glues. However, she cautions that one approved molecule does not necessarily validate other targets, mechanisms, or compound pharmacologies.

2. Beyond Cereblon: Expanding The E3 Ligase Universe 7/23/2026

   Maria Soloveychik says her company was founded to tackle challenging targets using proximity-based modalities, beginning with PPI disruption before expanding into novel small-molecule molecular glue degraders.

3. 600 Ligases, Endless Possibilities 7/23/2026

   Maria Soloveychik says more than 600 E3 ligases offer a large opportunity for targeted protein degradation, with efforts underway to develop ligands against many of them.

4. Which Discovery Technologies Help Solve Degrader Assay Gaps 7/23/2026

   Johannes Yeh says degrader discovery requires robust screening systems to measure target engagement, ternary complex formation, stability, and degradation, supported by tools such as CRISPR, shRNA, and proteomics.

5. PROTACs Offer Faster Proof Of Concept, But Glues May Broaden Patient Access 7/23/2026

   Maria Soloveychik says PROTACs are often easier to design rationally because they can be built from known ligands and optimized through linker chemistry, making them useful for early clinical proof of concept.

6. More Approvals, Broader Indications Could Make TPD A Mainstream Modality 7/23/2026

   Johannes Yeh says targeted protein degradation will feel mainstream when the field sees more FDA approvals, stronger clinical follow-up, and expansion beyond oncology into areas such as cardiovascular disease, Alzheimer’s, autoimmune disease, and diabetes.